Veru

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$0.47-$1.92
Market Cap
$77.3M
Shares Short
15M

Financials

See more
Revenue (12 Mos)
$16.8M
Revenue Growth (YoY)
18.3%
Gross Profit (12 Mos)
$5.8M
Diluted EPS
-$0.21

News

See more

Yahoo Finance • 24 days ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Yahoo Finance • last month

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Yahoo Finance • last year

Veru Announces Proposed Public Offering of Common Stock

Yahoo Finance • last year

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

About

CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
CFO
Ms. Michele Greco CPA
Address
2916 North Miami Avenue, Miami, FL, United States, 33127
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
210